NASDAQ · Biotechnology

EXEL (EXEL) Stock

$55.73 +2.00% NASDAQ: EXEL Healthcare

Valuation

MetricValue
Price$55.73
Market Cap$14.01B
P/E Ratio16.55
P/B Ratio7.41
P/S Ratio5.62
EPS (TTM)$2.78
52-Week High$57.57
52-Week Low$33.76
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE42.49%
ROA34.50%
ROCE45.56%
Gross Margin96.44%
Operating Margin39.43%
Net Margin35.33%
Debt/Equity0.09
Current Ratio3.55

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.4B$1.6B$1.8B$2.2B$2.3B
Operating Profit$287.0M$201.0M$171.0M$605.0M$872.0M
Net Profit$231.0M$182.0M$208.0M$521.0M$783.0M
EPS$0.72$0.56$0.65$1.76$2.78
Op Margin20.0%12.5%9.3%27.9%37.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.6B$3.1B$2.9B$2.9B$2.8B
Total Liabilities$406.0M$583.0M$678.0M$703.0M$683.0M
Cash$647.0M$501.0M$263.0M$217.0M$482.0M
Borrowings$51.0M$190.0M$190.0M$191.0M$173.0M

Latest News

EXEL: Lowering target price to $61.00 Argus Research · Jul 15, 2026 Is Exelixis (EXEL) Expensive After Its Recent Rally Or Still Undervalued? Simply Wall St. · Jul 11, 2026 Exelixis (EXEL) Stock Trades At A Discount After Its 236% Run Simply Wall St. · Jul 11, 2026 3 Under-the-Radar Stocks to Buy and Hold Motley Fool · Jul 10, 2026 EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth? Zacks · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$401.0M$363.0M$333.0M$700.0M$884.0M
Investing Cash Flow$-107.0M$-663.0M$-190.0M$-183.0M$311.0M
Financing Cash Flow$-15.0M$1.0M$-546.0M$-629.0M$-1.0B
Net Cash Flow$343.0M$-161.0M$-240.0M$-46.0M$265.0M
Free Cash Flow$337.0M$224.0M$170.0M$634.0M$844.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.31
EV / EBITDA13.05
FCF Yield8.63%
Quick Ratio3.38
Interest Coverage0.00
Return 1Y43.67%
Return 3Y143.08%
Return 5Y188.73%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGN $155.19 -2.88% 27.63 $11.11B 0.00%
BBIO $76.49 -0.13% -22.17 $14.98B 0.00%
BMRN $64.99 -0.37% 41.31 $12.56B 0.00%
CAI $24.97 -2.06% 49.96 $7.06B 0.00%
HALO $107.65 +1.09% 23.58 $12.77B 0.00%

About EXEL

EXEL is led by CEO Michael Morrissey, employs 1,077 people, headquartered in Alameda, US, publicly traded since 2000.

EXEL stock trades at $55.73 with a market capitalization of $14.01B. The stock is valued at a price-to-earnings (P/E) ratio of 16.55, price-to-book of 7.41, price-to-sales of 5.62. Over the past 52 weeks the stock has ranged between $33.76 and $57.57, and currently trades 3.2% below its 52-week high.

On profitability, EXEL generates a return on equity (ROE) of 42.49% — well above the market average, a sign of a high-quality business, return on capital employed of 45.56%, an operating margin of 39.43%, a net profit margin of 35.33%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1164.19 +0.64% JNJ Drug Manufacturers - General $270.06 +1.58% ABBV Drug Manufacturers - General $261.00 +1.79% MRK Drug Manufacturers - General $149.18 +0.96% UNH Medical - Healthcare Plans $395.60 +1.59% NVS Drug Manufacturers - General $161.66 +6.31% AZN Drug Manufacturers - General $161.97 -0.10% AMGN Drug Manufacturers - General $437.27 +1.72% TMO Medical - Diagnostics & Research $602.27 -2.40% NVO Biotechnology $45.29 -0.09% ABT Medical - Devices $109.56 -0.72% GILD Drug Manufacturers - General $149.07 +1.86%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides